DermaXon is a drug discovery and development company providing first in-class drug candidates. DermaXon works to discover and develop novel therapeutic strategies to treat and prevent life-threatening skin diseases and disorders. The company was founded in 2013 by Dr. Philippe Diaz Professor at the Department of Biomedical Sciences at the University of Montana. The company core technology is based on the design and development of small molecules and proteolysis targeting chimera (PROTAC) modulating understudied targets. DermaXon uses medicinal chemistry, molecular biology, artificial intelligence and machine learning, and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by these molecules and triggering the initiation of diseases and disorders.